Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13763602 | 0.85 | TRPA1 (0.62) | TRPA1CSF1REGFRMAPTHTR1A | |
| SCHEMBL8137955 | 0.81 | TRPA1 (0.62) | TRPA1CSF1REGFRMAPTHTR1A | |
| SCHEMBL28050003 | 0.79 | NR4A2 (0.47) | EGFRATMLCK | |
| SCHEMBL13763743 | 0.79 | TRPA1 (0.57) | TRPA1CSF1REGFRMAPTHTR1A | |
| SCHEMBL13757426 | 0.78 | TRPA1 (0.56) | TRPA1CSF1REGFRMAPTHTR1A | |
| SCHEMBL12141884 | 0.78 | EGFR (0.51) | TRPA1CSF1REGFRMAPTHTR1A | |
| SCHEMBL20782877 | 0.78 | LCK (0.57) | TRPA1EGFRFLT3LCKSRC | |
| SCHEMBL15483521 | 0.76 | ALDH1A1 (0.36) | TRPA1CSF1RMAPTSRC | |
| SCHEMBL13385161 | 0.75 | TRPA1 (0.56) | TRPA1MAPTATMHTR1AADRA1D | |
| SCHEMBL12762533 | 0.75 | HTR1A (0.52) | HTR1AADRA1DADRA1AADRA1BAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | TRPA1 4344/4885CSF1R 4645/4885EGFR 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.